Review
Biochemistry & Molecular Biology
Alen Roncevic, Nenad Koruga, Anamarija Soldo Koruga, Robert Roncevic, Tatjana Rotim, Tihana Simundic, Domagoj Kretic, Marija Peric, Tajana Turk, Damir Stimac
Summary: Glioblastoma (GBM) is a highly aggressive glial tumor in the central nervous system. Current standard treatments only offer a median survival of 15 months. Tissue samples obtained during surgery are crucial for GBM diagnosis, and there is significant room for improvement in the current treatment methods.
Article
Multidisciplinary Sciences
Mahdie Mousavi, Fereshteh Koosha, Ali Neshastehriz
Summary: A novel nanocomplex, SPIO@AuNP-Cisplatin-Alginate (SACA), was synthesized and characterized. The combination of SACA and 6 MV X-ray significantly decreased the viability of U87MG cells and increased apoptosis, indicating that this nanocomplex effectively enhanced the radiosensitivity of cancer cells.
Review
Immunology
Boyuan Huang, Xuesong Li, Yuntao Li, Jin Zhang, Zhitao Zong, Hongbo Zhang
Summary: Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor in the central nervous system. Immunotherapy has shown promising results in the treatment of GBM, but future developments will require an integrated approach with various treatment modalities and specific targeted therapies for the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Jingwei Zhang, Zeyu Wang, Hao Zhang, Ziyu Dai, Xisong Liang, Shuwang Li, Xun Zhang, Fangkun Liu, Zhixiong Liu, Kui Yang, Quan Cheng
Summary: This study investigates the role of RING finger proteins in low-grade glioma (LGG) and identifies three key markers related to immune infiltration, which may serve as novel therapeutic targets for immunotherapy in the future.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Alejandro Rodriguez-Camacho, Jose Guillermo Flores-Vazquez, Julia Moscardini-Martelli, Jorge Alejandro Torres-Rios, Alejandro Olmos-Guzman, Cindy Sharon Ortiz-Arce, Dharely Raquel Cid-Sanchez, Samuel Rosales Perez, Monsserrat Del Sagrario Macias-Gonzalez, Laura Crystell Hernandez-Sanchez, Juan Carlos Heredia-Gutierrez, Gabriel Alejandro Contreras-Palafox, Jose de Jesus Emilio Suarez-Campos, Miguel Angel Celis-Lopez, Guillermo Axayacalt Gutierrez-Aceves, Sergio Moreno-Jimenez
Summary: Glioblastoma is a lethal tumor with limited treatment options. Efforts are being made in various research areas to find new therapies that can improve patient survival and quality of life.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Feng Xiao, Zhenli Long, Yun Guo, Hong Zhu, Zhe Zhang, Yao Xiao, Guowen Hu, Qing Yang, Kai Huang, Hua Guo
Summary: Objective: MAGOH plays a pivotal role in various tumors, but its specific contribution in lower-grade glioma (LGG) is still unknown. Methods: Pan-cancer analysis was conducted to investigate the expression characteristics and prognostic significance of MAGOH in multiple tumors. Results: Increased MAGOH expression was associated with adverse prognosis in LGG patients and correlated with immune-related markers, immune cell infiltration, gene mutations, and responses to chemotherapy. In vitro studies confirmed the essential role of MAGOH in cell proliferation in LGG.
Article
Cell Biology
Feng Xiao, Hong Zhu, Yun Guo, Zhe Zhang, Gufeng Sun, Kai Huang, Hua Guo, Guowen Hu
Summary: Through comprehensive tumor analysis, we found that DUSP10 is upregulated in various tumors and is associated with poor prognosis. In lower-grade glioma, DUSP10 expression is closely correlated with clinicopathologic features, prognosis, biological processes, immune traits, gene variations, and treatment responses. In vitro studies showed that DUSP10 is abnormally increased and essential for cell proliferation in lower-grade glioma. In conclusion, DUSP10 is an independent prognostic indicator and may serve as a novel target for targeted therapy in lower-grade glioma.
Article
Oncology
Hong-Jian Wei, Pavan S. Upadhyayula, Antonios N. Pouliopoulos, Zachary K. Englander, Xu Zhang, Chia-Ing Jan, Jia Guo, Angeliki Mela, Zhiguo Zhang, Tony J. C. Wang, Jeffrey N. Bruce, Peter D. Canoll, Neil A. Feldstein, Stergios Zacharoulis, Elisa E. Konofagou, Cheng-Chia Wu
Summary: Glioblastoma is a devastating disease with poor treatment outcomes. It has been found that using focused ultrasound to open the blood-brain barrier can enhance drug delivery, increasing etoposide concentration in the brain and leading to local control and survival benefits for tumors.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Biotechnology & Applied Microbiology
Kunshan He, Chongwei Chi, Deling Li, Jingjing Zhang, Gang Niu, Fangqiao Lv, Junmei Wang, Wenqiang Che, Liwei Zhang, Nan Ji, Zhaohui Zhu, Jie Tian, Xiaoyuan Chen
Summary: The GBM-specific fluorescent IRDye800-BBN achieved a complete resection rate of 82.76% in 29 GBM patients, with a sensitivity and specificity of 94.44% and 88.24%, respectively. This specific fluorescence may help neurosurgeons accurately identify tumor boundaries and potentially improve patient survival outcomes.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2021)
Review
Immunology
Payal Aggarwal, Wen Luo, Katherine C. C. Pehlivan, Hai Hoang, Prajwal Rajappa, Timothy P. P. Cripe, Kevin A. A. Cassady, Dean A. A. Lee, Mitchell S. S. Cairo
Summary: This article examines the differences and similarities between high grade gliomas in adults and children, including epidemiology, etiology, pathogenesis, and treatment approaches. Although there are differences in clinical presentation, molecular biology background, and response to chemotherapy, both types of gliomas respond to immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Chao Lin, Ning Wang, Chengyan Xu
Summary: Glioma is a solid tumor composed of both neoplastic and non-neoplastic components. Glioma-associated macrophages and microglia (GAMs) are crucial in regulating tumor growth, invasion, and recurrence in the glioma tumor microenvironment. This review provides an overview of the intricate relationship between GAMs and the glioma tumor microenvironment, as well as a summary of immunotherapies targeting GAMs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Immunology
Zhile Wang, Fucun Xie, Yijun Wu, Li Wang, Yi Bai, Junyu Long, Xiang Wang
Summary: The study showed a close correlation between high ICI scores and high TMB values, with ICI scores serving as reliable prognostic predictors. The predictive model established demonstrated significant superiority among glioma patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Eric J. Lehrer, Brianna M. Jones, Kunal K. Sindhu, Daniel R. Dickstein, Mira Cohen, Stanislav Lazarev, Alfredo Quinones-Hinojosa, Sheryl Green, Daniel M. Trifiletti
Summary: Stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) are commonly used in the treatment of brain metastases. However, their use in primary brain tumors is still controversial. Meningiomas respond well to treatment, but higher grade meningiomas are resistant. Glioblastoma has a poor prognosis, but preoperative SRS may enhance the immune response to ICIs.
Article
Cell Biology
Cong Luo, Zhixiong Liu, Wenrui Ye, Fangkun Liu
Summary: This study identified immune infiltrates associated with overall survival in lower grade glioma patients and obtained 44 hub genes to construct an immune infiltration-related signature. The signature showed potential as a prognostic biomarker for glioma patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)